A drug company once run by Martin Shkreli, Pharma Bro, has agreed to settle a proposed class action alleging it illegally tried to block generic versions of a life-saving medication whose price he famously raised, reported Reuters.
Vyera Pharmaceuticals in a proposed settlement filed on Friday in Manhattan federal court agreed to pay up to US$28 million, money that would derive from the up to US$40 million it already agreed last month to pay in a related case.
That case was brought by the US Federal Trade Commission (FTC) and seven states. A federal judge later in the FTC’s case barred Shkreli from the pharmaceutical industry for life and ordered him to pay US$64.6 million.
Related: “Pharma Bro” Shkreli Loses Bid To Delay Antitrust Trial
Shkreli, who ran Vyera as chief executive when it was known as Turing Pharmaceuticals, is serving a seven-year prison sentence for securities fraud in an unrelated case.
Friday’s settlement would resolve claims that Blue Cross and Blue Shield of Minnesota brought on behalf of other third-party payers that purchased Daraprim, which treats toxoplasmosis, a parasitic infection that threatens people with weakened immune systems.
Vyera; its parent company, Phoenixus AG; Shkreli; and former Vyera CEO Kevin Mulleady were all named as defendants and all agreed to settle the case. The deal requires the approval of US District Judge Denise Cote.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
